Full-Time

Market Development Manager

Urology

Confirmed live in the last 24 hours

Telix Pharmaceuticals

Telix Pharmaceuticals

501-1,000 employees

Develops targeted radiation therapies for cancer

No salary listed

Senior

Remote in USA

Territory includes: AK, WA, OR, ID, WY, ND, SD, NE, KS, IA, MO, WI, MT

Category
Strategy Development
Business Development
Business & Strategy
Required Skills
Market Research
Sales
Marketing
Requirements
  • Bachelor's degree in a relevant field (Medical, Pharmaceutical Sciences, Marketing, or related discipline) required.
  • Proven track record (5+ years) in market development, business development, or marketing roles within the pharmaceutical or healthcare industry, with a focus on urology.
  • Strong analytical and strategic thinking skills.
  • Excellent communication, negotiation, and relationship-building skills.
  • Ability to work independently and collaboratively in cross-functional teams.
  • In-depth knowledge of urology and oncology markets, including industry trends and key stakeholders.
  • Familiarity with pharmaceutical regulatory requirements (e.g., FDA) is a plus.
  • Key Opinion Leader development required.
  • Exceptional interpersonal and communication skills with a strong urology-focused approach.
  • Familiarity with urology industry regulations, compliance considerations, and ethical guidelines.
  • Proven track record in developing and executing successful marketing strategies.
  • Passion for patient advocacy and ensuring their best interests are represented.
  • Self-motivated, results-driven, and capable of autonomously driving urology initiatives, marketing efforts, and patient advocacy.
  • Excellent organizational and time management abilities.
  • 75% overnight travel
Responsibilities
  • Cultivate strong relationships with urologists, urology clinics, medical professionals, and C-Level key stakeholders within the urology field, including LUGPA’s, URO GPO’s, and Private Equity groups.
  • Plan and execute engaging urology-focused educational events, workshops, and seminars to share the latest advancements, research insights, and therapeutic possibilities.
  • Identify and leverage strategic opportunities for referrals and collaborative initiatives, aligning with urologists' needs and patient demographics.
  • Conduct in-depth market research to understand the dynamics, trends, and opportunities within the urology and oncology segments, including competitive analysis and customer needs assessment.
  • Develop and execute comprehensive market development strategies tailored to the Urology portfolio, including product positioning, pricing strategies, and market entry plans.
  • Collaborate closely with the sales team to identify and pursue target markets, customer segments, and new business opportunities. Provide support in the negotiation and closure of key deals.
  • Develop and manage budgets for market development initiatives, ensuring efficient allocation of resources to maximize ROI.
  • Define and monitor key performance indicators (KPIs) to measure the success of market development strategies. Provide regular reports and updates to the leadership team.
  • Develop and implement targeted marketing strategies to promote, raise brand awareness, increase utilization and position Telix as a leader in nuclear medicine innovation within top 100 customers. Manage direct-to-consumer marketing campaigns at the local level within target markets, including reporting and metrics of campaigns.
  • Champion patient-centric care by ensuring that all initiatives, interactions, and strategies prioritize the well-being and best interests of patients. Support and participate in local patient advocacy opportunities and events in targeted markets.
  • Ensure all urology-related interactions, marketing campaigns, and initiatives comply with relevant industry regulations, ethical standards, and company policies.
Desired Qualifications
  • Familiarity with pharmaceutical regulatory requirements (e.g., FDA) is a plus.
Telix Pharmaceuticals

Telix Pharmaceuticals

View

Telix Pharmaceuticals develops and sells biopharmaceutical products aimed at improving the diagnosis and treatment of cancer and rare diseases. Their products use targeted radiation to enhance treatment decisions and offer personalized therapy for conditions that lack effective solutions. The company focuses on areas such as prostate and kidney cancers, glioma, sarcoma, and bone marrow conditioning. Telix has a well-established global supply chain to manufacture and distribute its products to healthcare providers and patients. Unlike many competitors, Telix emphasizes sustainability, patient care, and ethical practices in its operations. The company's goal is to create sustainable value for patients, shareholders, and employees while improving the quality of life for those affected by complex diseases.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Melbourne, Australia

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA's priority review for TLX250-CDx highlights its potential in kidney cancer diagnostics.
  • Illuccix approval in the UK addresses PSMA-PET imaging agent shortages, boosting market share.
  • Promising IPAX-Linz study results enhance Telix's neuro-oncology portfolio with TLX101.

What critics are saying

  • Increased competition in targeted radiation therapy may impact Telix's market share.
  • Supply shortages of radioisotopes like gallium-68 could disrupt production and distribution.
  • Regulatory delays in key markets could hinder the commercial launch of new products.

What makes Telix Pharmaceuticals unique

  • Telix focuses on molecularly-targeted radiation therapy for prostate, renal, and glioblastoma cancers.
  • The company integrates sustainability and patient care into its biopharmaceutical operations.
  • Telix's global supply chain ensures worldwide availability of its diagnostic and therapeutic products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Annual Performance Bonus

Equity-Based Incentive Program

Paid Vacation

Paid Wellness Days

Hybrid Work Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Telix Pharmaceuticals
Apr 25th, 2025
AUA25: Telix to Showcase Urologic Pipeline at AUA: ProstACT Global, Illuccix(R) and Zircaix(R)

AUA25: Telix to showcase urologic pipeline at AUA: ProstACT Global, Illuccix(R) and zircaix(r).

PR Newswire
Apr 15th, 2025
Ipax-Linz Study Reports Promising Efficacy For Tlx101 Glioma Therapy Candidate

MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan[1]) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study[2]. IPAX-Linz is a single-arm Phase 2 investigator-initiated trial (IIT). IPAX-Linz evaluates the safety, tolerability and preliminary efficacy of TLX101 therapy, in combination with external beam radiation therapy (EBRT). The target patient population is patients at first or second recurrence with high-grade gliomas (HGG), including glioblastoma. Treatment with TLX101 was well tolerated with no serious adverse events reported. IPAX-Linz demonstrated encouraging preliminary efficacy data, indicating a median overall survival (OS) of 12.4 months from the initiation of treatment with TLX101, or 32.2 months from initial diagnosis[3]

Siam News Network
Apr 6th, 2025
Telix Appoints Paul Schaffer as Chief Technology Officer

MELBOURNE, Australia and INDIANAPOLIS, April 7, 2025 /PRNewswire/ - Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today.

Telix Pharmaceuticals
Apr 3rd, 2025
Anne Whitaker Appointed as Non-Executive Director

Telix today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 2025[1].

Pipeline Review
Apr 2nd, 2025
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

Telix holds the exclusive worldwide rights to develop and commercialize radiolabelled forms of olaratumab, which was originally developed by Eli Lilly and Company (Lilly).